Results 1 to 10 of about 9,424 (215)
Molecular Metabolism, 2018 Objectives: Glycemic control by medical treatment represents one therapeutic strategy for diabetic patients. The Na+-d-glucose cotransporter 1 (SGLT1) is currently of high interest in this context.
Hermann Koepsell +2 more
exaly +5 more sources
Molecular Oncology, 2019 Sodium/glucose cotransporter 1 (SGLT1), an essential active glucose transport protein that helps maintain high intracellular glucose levels, was previously shown to interact with epidermal growth factor receptor (EGFR); the SGLT1–EGFR interaction ...
Yihua Wang, Wei-Chien Huang, Rob Ewing
exaly +4 more sources
SGLT1: A Potential Drug Target for Cardiovascular Disease
Drug Design, Development and Therapy, 2023 Mengnan Zhao,* Na Li,* Hong Zhou Department of Endocrinology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hong Zhou, Department
Na Li
exaly +5 more sources
SGLT1 Inhibition Attenuates Apoptosis in Diabetic Cardiomyopathy via the JNK and p38 Pathway
Frontiers in Pharmacology, 2021 Background: Recent studies have revealed that a novel selective sodium-glucose cotransporter 1 (SGLT1) inhibiton has shown beneficial effects in cardiovascular diseases. However, the question of whether SGLT1 inhibition influences diabetic cardiomyopathy
Shimin Sun, Liping Meng, Zhenzhu Sun
exaly +3 more sources
Pancreatic α-cell sodium-glucose cotransporter 1 (SGLT1) does not appear to contribute to hyperglucagonemia and glucose intolerance in diabetic mice [PDF]
Endocrine JournalPancreatic α-cells secrete glucagon, a hormone that elevates blood glucose levels. In type 2 diabetes, high plasma glucagon levels are associated with hyperglycemia. However, the underlying mechanisms of increasing glucagon secretion remain unclear.
Yuichi Ikeuchi +9 more
doaj +2 more sources
The Impact of SGLT1 Inhibition on Frailty and Sarcopenia: A Mediation Mendelian Randomization Study
Journal of Cachexia, Sarcopenia and MuscleBackground Although pharmacological effects of SGLT2 inhibitors on the development of frailty and sarcopenia were known, the role of SGLT1 remained less clear. The present study investigated the possible effect of SGLT1 inhibition on these conditions and
Yu-Jie Zhang, Bang-Bang Huang
exaly +2 more sources
Sodium-glucose transporters SGLT1 and SGLT2 in equine renal, hepatic and pancreatic tissue [PDF]
BMC Veterinary ResearchBackground Insulin dysregulation is a hallmark of equine metabolic syndrome (EMS), and in recent years, pharmacological treatment with sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have shown promise in reducing the risk of hyperinsulinemia ...
Camilla Anger-Håål +4 more
doaj +2 more sources
SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis
Frontiers in Pharmacology, 2021 Background: Cardiac fibroblast (CF) activation is a hallmark feature of cardiac fibrosis in diabetic cardiomyopathy (DCM). Inhibition of the sodium-dependent glucose transporter 1 (SGLT1) attenuates cardiomyocyte apoptosis and delays the development of ...
Hui Lin +4 more
doaj +1 more source
Frontiers in Bioscience-Landmark, 2022 Background: Diabetic retinopathy (DR) is a major cause of blindness globally. Sodium Glucose Cotransporter-2 (SGLT2) inhibitors have been demonstrated to exert cardiorenal protection in patients with diabetes.
Lakshini Y. Herat +5 more
doaj +1 more source
The Sympathetic Nervous System Regulates Sodium Glucose Co-Transporter 1 Expression in the Kidney
Biomedicines, 2023 Hyperactivation of the sympathetic nervous system (SNS) has been demonstrated in various conditions including obesity, hypertension and type 2 diabetes. Elevated levels of the major neurotransmitter of the SNS, norepinephrine (NE), is a cardinal feature ...
Jennifer Matthews +4 more
doaj +1 more source